A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion.
Also in this 12-page issue: GM Cancer Research Foundation awards annual prizes to four scientists.
Age-adjusted cancer incidence and mortality down slightly, annual report finds.
Bills in House, Senate, would give FDA authority over tobacco products.
Surgeon General’s report adds to list of smoking-related cancers, other diseases.
ASCO honors physicians for clinical trials participation.
President’s Cancer Panel urges comprehensive health care reform, provision of services for cancer survivors.
Funding opportunities listed.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help
